Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Plasmacytoma 1Osteosarcoma 1Neuroblastoma 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1Cholangiocarcinoma 1Carcinoma, Basal Cell 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Photochemotherapy 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Radiofrequency Ablation 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Drug Therapy 3Dihematoporphyrin Ether 3Dexamethasone 3Cholangiopancreatography, Endoscopic Retrograde 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × silmitasertib × Clear all
NCT02128282 2021-10-22

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Senhwa Biosciences, Inc.

Phase 1/2 Completed
127 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡